Nofi Michael reported option exercise involving 10,937 derivative units of Edgewise Therapeutics, Inc. at $0.00 for $0 on Nov 10, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chief Financial Officer
Chief Financial Officer
Filed Nov 10, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
10,937Restricted Stock Units
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
32,813Direct
Trade date
Nov 10, 2026Option exercise
Filed
Nov 10, 2026, 5:21 PM ET0-day reporting delay
Accession
0001705477-26-000003Code M · Transaction 397368
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 10, 2026Option exercise10,937$0.00$0Trade 397366
Nov 10, 2026Sell4,442$45.43−$201,786.73Trade 397367
3 transaction rows in this filing. Joint filers share the same rows.

EWTX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
EWTX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 17, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago +0.4%1w ago 0%1d ago 0%
Returns since7d30d90d180d1y

Footnotes in full

F1: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person F2: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $45.165 to $45.57, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on November 10, 2026.